PF-3052334

PF-3052334 is an orally active, hepatically selective HMG-CoA reductase inhibitor with an IC50 of 1.9 nM. PF-3052334 inhibits cholesterol synthesis, with IC50 values of 0.9 and 730 nM in hepatocytes and muscle cells, respectively. PF-3052334 can be used to study hypercholesterolemia[1].

Product Specifications

CAS Number

[887702-61-6]

UNSPSC

12352005

Target

HMG-CoA Reductase (HMGCR)

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Metabolic Disease

Smiles

O=C(O[Na])C[C@H](O)C[C@H](O)CCC1=C(C(C)C)C(C(NCC2=CC=C(C=C2)C)=O)=NN1C3=CC=C(C=C3)F

Molecular Formula

C28H33FN3NaO5

Molecular Weight

533.57

References & Citations

[1]Pfefferkorn JA, et al. Substituted Pyrazoles as Hepatoselective HMG-CoA Reductase Inhibitors: Discovery of (3 R, 5 R) -7-[2- (4-Fluoro-phenyl) -4-isopropyl-5- (4-methyl-benzylcarbamoyl) -2 H-pyrazol-3-yl]-3, 5-dihydroxyheptanoic Acid (PF-3052334) as a Candidate for the Treatment of Hypercholesterolemia. Journal of medicinal chemistry. 2008 Jan 10;51 (1) :31-45.